
51 - 200 employees
Founded 2019
🏥 Healthcare
🧬 Biotechnology
💊 Pharmaceuticals
💰 $175.3M Post IPO equity on 2024-03
Healthcare • Biotechnology • Pharmaceuticals
NewAmsterdam Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular disease and other lipid-related conditions. The company is advancing obicetrapib, a CETP inhibitor, and other programs aimed at lowering LDL-C and reducing cardiovascular risk for patients who have unmet needs despite existing lipid-lowering treatments. NewAmsterdam emphasizes science-backed development, clinical trials, and patient-focused initiatives.
🕒 July 11
Associate Director of Quality Assurance managing drug substance and product quality at NewAmsterdam Pharma. Ensuring compliance with regulations and collaborating with cross-functional teams in a remote position.
🇺🇸 United States – Remote
💰 $175.3M Post IPO equity on 2024-03
⏰ Full Time
🟠 Senior
🔧 QA Engineer (Quality Assurance)
Google Cloud Platform
🕒 July 2
Senior Director overseeing IT applications for Finance, Legal, and HR at NewAmsterdam Pharma. Leading implementations and supporting key business functions while managing vendor relationships.
🕒 June 25
Senior Manager in CMC Regulatory Affairs at NewAmsterdam Pharma supporting global regulatory strategies for clinical and marketing applications.
🕒 June 19
Director, Commercial Supply Chain for a pre-commercial biotech supporting product launches and operational readiness. Driving supply planning and compliance while coordinating with internal and external stakeholders.
🕒 May 27
Manager of Finance at NewAmsterdam Pharma focusing on financial management and FP&A support to enhance business performance. Collaborating with business leaders in driving strategic decision-making.
🔔 Pennsylvania – Remote
💰 $175.3M Post IPO equity on 2024-03
⏰ Full Time
🟡 Mid-level
🟠 Senior
💸 Financial Planning and Analysis (FP&A)
🕒 March 14
Associate Director managing clinical trials at NewAmsterdam Pharma. Ensuring regulatory compliance and operational excellence in cardiovascular disease research.